TY  - JOUR 
AU  - Blanco Durango, Belén
AU  - Perez Simon, José Antonio
AU  - Sánchez Abarca, Luis Ignacio
AU  - Caballero Velazquez, Teresa
AU  - Gutierrez Cossio, Silvia
AU  - Hernández Campo, Pilar
AU  - Diez Campelo, María
AU  - Herrero Sánchez, María del Carmen
AU  - Rodríguez Serrano, Concepción
AU  - Santamaría Quesada, Carlos
AU  - Sánchez Guijo, Fermín
AU  - Cañizo Fernández-Roldán, Consuelo del
AU  - San Miguel Izquierdo, Jesús F.
PY  - 2009
SN  - 0390-6078
UR  - https://uvadoc.uva.es/handle/10324/55178
AB  - Background In vitro depletion of alloreactive T cells using the proteasome inhibitor bortezomib is a promising approach to prevent graft-versus-host disease after allogeneic stem cell transplantation. We have previously described the ability of...
LA  - eng
PB  - Ferrata Storti Foundation
KW  - Cell Biology
KW  - Graft versus host disease
KW  - Cell transplantation
KW  - Trasplante de células
KW  - Medical microbiology
KW  - Pharmacology
TI  - Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population
DO  - 10.3324/haematol.2008.005017
ER  -